X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (52) 52
oncology (50) 50
index medicus (42) 42
female (33) 33
chemotherapy (32) 32
adult (31) 31
middle aged (31) 31
aged (30) 30
cancer (28) 28
male (26) 26
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
treatment outcome (21) 21
breast neoplasms - drug therapy (17) 17
analysis (15) 15
disease-free survival (15) 15
aged, 80 and over (12) 12
prognosis (12) 12
breast neoplasms - pathology (11) 11
metastasis (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
care and treatment (9) 9
kaplan-meier estimate (9) 9
neoplasm metastasis (9) 9
paclitaxel (9) 9
taxoids - administration & dosage (9) 9
trial (9) 9
adenocarcinoma - drug therapy (8) 8
breast neoplasms - mortality (8) 8
cisplatin - administration & dosage (8) 8
clinical trials (8) 8
drug administration schedule (8) 8
hematology, oncology and palliative medicine (8) 8
survival (8) 8
therapy (8) 8
tumors (8) 8
combined modality therapy (7) 7
docetaxel (7) 7
fluorouracil - administration & dosage (7) 7
multicenter (7) 7
survival analysis (7) 7
survival rate (7) 7
trastuzumab (7) 7
1st-line treatment (6) 6
antineoplastic agents - therapeutic use (6) 6
colorectal cancer (6) 6
combination (6) 6
efficacy (6) 6
follow-up studies (6) 6
germ cell tumors (6) 6
neoadjuvant therapy (6) 6
neoplasm staging (6) 6
proportional hazards models (6) 6
quality of life (6) 6
research (6) 6
retrospective studies (6) 6
safety (6) 6
studies (6) 6
urology (6) 6
urology & nephrology (6) 6
adenocarcinoma - pathology (5) 5
antineoplastic agents - administration & dosage (5) 5
antineoplastic agents - adverse effects (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
breast cancer (5) 5
cancer therapies (5) 5
carcinoma (5) 5
cisplatin (5) 5
disease progression (5) 5
drug therapy (5) 5
gemcitabine (5) 5
genetic aspects (5) 5
medicine & public health (5) 5
open-label (5) 5
patients (5) 5
prognostic factors (5) 5
randomized-trial (5) 5
russia (5) 5
stomach neoplasms - drug therapy (5) 5
supportive care (5) 5
testicular neoplasms - pathology (5) 5
adolescent (4) 4
animals (4) 4
antibodies, monoclonal, humanized - administration & dosage (4) 4
article (4) 4
capecitabine (4) 4
cell lung-cancer (4) 4
chemotherapy, adjuvant (4) 4
doxorubicin (4) 4
esophageal cancer (4) 4
esophageal neoplasms - drug therapy (4) 4
europe (4) 4
life sciences (4) 4
neoplasms, germ cell and embryonal - genetics (4) 4
oncology, experimental (4) 4
placebo (4) 4
plus (4) 4
prospective studies (4) 4
radiotherapy (4) 4
risk (4) 4
stomach neoplasms - pathology (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 6, pp. 640 - 647
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 18, pp. 1691 - 1703
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 33, pp. 5529 - 5537
Purpose TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth... 
AROMATASE INHIBITOR | OVEREXPRESSION | ONCOLOGY | SERUM HER-2/NEU | TAMOXIFEN | RESISTANCE | LETROZOLE | ENDOCRINE THERAPY | COMBINATION | HER2 | ESTROGEN-RECEPTOR | Receptors, Estrogen - blood | Triazoles - administration & dosage | Triazoles - adverse effects | Confidence Intervals | Postmenopause - drug effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antibodies, Monoclonal, Humanized | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Adenocarcinoma - metabolism | Statistics, Nonparametric | Aged, 80 and over | Female | Drug Administration Schedule | Administration, Oral | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Adenocarcinoma - secondary | Biomarkers, Tumor - blood | Disease-Free Survival | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Breast Neoplasms - pathology | Survival Analysis | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Nitriles - adverse effects | Receptors, Progesterone - blood | Receptor, ErbB-2 - blood | Trastuzumab | Adenocarcinoma - mortality | Index Medicus
Journal Article
by Pujade-Lauraine, Eric and Ledermann, Jonathan A and Selle, Frédéric and Gebski, Val and Penson, Richard T and Oza, Amit M and Korach, Jacob and Huzarski, Tomasz and Poveda, Andrés and Pignata, Sandro and Friedlander, Michael and Colombo, Nicoletta and Harter, Philipp and Fujiwara, Keiichi and Ray-Coquard, Isabelle and Banerjee, Susana and Liu, Joyce and Lowe, Elizabeth S and Bloomfield, Ralph and Pautier, Patricia and Korach, Jacob and Huzarski, Tomasz and Byrski, Tomasz and Pautier, Patricia and Friedlander, Michael and Harter, Philipp and Colombo, Nicoletta and Pignata, Sandro and Scambia, Giovanni and Nicoletto, Maria and Nussey, Fiona and Clamp, Andrew and Penson, Richard and Oza, Amit and Poveda Velasco, Andrés and Rodrigues, Manuel and Lotz, Jean-Pierre and Selle, Frédéric and Ray-Coquard, Isabelle and Provencher, Diane and Prat Aparicio, Aleix and Vidal Boixader, Laura and Scott, Clare and Tamura, Kenji and Yunokawa, Mayu and Lisyanskaya, Alla and Medioni, Jacques and Pécuchet, Nicolas and Dubot, Coraline and de la Motte Rouge, Thibault and Kaminsky, Marie-Christine and Weber, Béatrice and Lortholary, Alain and Parkinson, Christine and Ledermann, Jonathan and Williams, Sarah and Banerjee, Susana and Cosin, Jonathan and Hoffman, James and Plante, Marie and Covens, Allan and Sonke, Gabe and Joly, Florence and Floquet, Anne and Hirte, Holger and Amit, Amnon and Park-Simon, Tjoung-Won and Matsumoto, Koji and Tjulandin, Sergei and Kim, Jae Hoon and Gladieff, Laurence and Sabbatini, Roberto and O'Malley, David and Timmins, Patrick and Kredentser, Daniel and Laínez Milagro, Nuria and Barretina Ginesta, Maria Pilar and Tibau Martorell, Ariadna and Gómez de Liaño Lista, Alfonso and Ojeda González, Belén and Mileshkin, Linda and Mandai, Masaki and Boere, Ingrid and Ottevanger, Petronella and Nam, Joo-Hyun and Filho, Elias and Hamizi, Salima and Cognetti, Francesco and Warshal, David and Dickson-Michelson, Elizabeth and Kamelle, Scott and McKenzie, Nathalie and Rodriguez, Gustavo and Armstrong, Deborah and Chalas, Eva and Celano, Paul and Behbakht, Kian and Davidson, Susan and Welch, Stephen and Helpman, Limor and ... and SOLO2/ENGOT-Ov21 investigators and SOLO2-ENGOT-Ov21 Investigators
The Lancet Oncology, ISSN 1470-2045, 09/2017, Volume 18, Issue 9, pp. 1274 - 1284
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2020, Volume 38, Issue 4_suppl, pp. 131 - 131
131 Background: Regorafenib is one of the standards of care in pts with chemorefractory mCRC. However, high toxicity is a common reason of treatment... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2007, Volume 357, Issue 17, pp. 1705 - 1715
Journal Article